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The global scale-up of antiretroviral therapy (ART) has 
resulted in HIV infection being transformed from an 
inevitably fatal disease to a chronic, albeit incurable, 
infection requiring life-long treatment.1 Increasing 
numbers of children infected through mother-to-child 
HIV transmission, who would have died in infancy in 
the pre-ART era, are now reaching adolescence and face 
the prospect of having to take ART daily with optimum 
adherence for the rest of their lives.2–4
In The Lancet HIV, the PENTA 16 trial group report the 
ﬁ ndings of the BREATHER study, an open-label, non-
inferiority trial, comparing continuous daily ART with 
short cycle treatment enabling 2 days oﬀ  treatment 
every week.5 199 participants aged 8–24 years who had 
been virally suppressed for at least 12 months before 
enrolment and were taking an ART regimen containing 
the long-acting drug efavirenz were recruited from 
11 countries worldwide. At 48 weeks, six (6%) of 
99 children in the short cycle treatment group versus 
seven (7%) of 100 in the continuous treatment group 
had virological rebound (HIV viral load >50 copies per 
mL; diﬀ erence –1·2%, 90% CI –7·3 to 4·9), showing that 
short cycle treatment is non-inferior to continuous 
treatment. There was no statistical diﬀ erence between 
the groups in the proportion of participants who 
developed major resistance mutations or in the 
proportion of adverse events. This is the ﬁ rst trial to 
show that controlled interruption seems to be safe in 
terms of both maintenance of viral suppression and 
emergence of drug resistance. Notably, the trial was 
done in geographically diverse settings and achieved an 
impressive retention rate with only one participant lost 
to follow-up. 
Children are expected to take ART for 20 years longer 
on average than adults and strategies that enable time 
oﬀ  ART could be an eﬀ ective way to reduce treatment 
fatigue.6 Additionally, reduced ART usage through 
short cycle treatment might provide potential cost 
savings. The short cycle treatment strategy was highly 
acceptable to participants, particularly because it 
enabled socialising at weekends, which is otherwise a 
key barrier to taking medication. Even patients who are 
virologically suppressed report intermittently missing 
drugs, and short cycle treatment provides regulated 
time oﬀ  medication and a legitimate way to miss 
doses.7 Of concern is that such a strategy might give 
out the message that missing doses is acceptable and 
seems not to aﬀ ect viral load. Therefore, appropriate 
counselling is crucial to ensure that the results are not 
misinterpreted and that patients understand that there 
is a maximum break in treatment of the designated 
2 days per week.
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In The Lancet HIV, Aghaizu and colleagues1 present 
results from their analysis of repeated, cross-sectional 
surveys coupled with anonymous HIV testing to try 
to explain why HIV incidence remains high in gay and 
bisexual men in London, UK. The authors sought to 
explain why incidence might be sustained, despite 
improvements in frequency of HIV testing and 
treatment uptake since 2000.
The ﬁ ndings show the value of repeated, behavioural 
surveillance of an HIV-aﬀ ected population, not 
only in the identiﬁ cation of behaviours that explain 
epidemic trends, but also to suggest potential areas for 
intervention.2,3 Sadly, few jurisdictions have initiated or 
sustained investment in behavioural surveillance,4 so, 
in many locations, the direction in which community 
norms are shifting and the practices that need attention 
Notably, the ﬁ ndings of this study are only 
generalisable to patients who are stable and well 
established on ART. The median time on ART before 
randomisation in this trial was 6 years and children 
had been virally suppressed for at least 12 months. 
Additionally, the results cannot be extrapolated to 
children who have had previous treatment failure, or to 
ART containing reduced doses of efavirenz (equivalent 
to 400 mg for adults) or indeed to other long-acting 
ART regimens. The follow-up period was short and the 
planned 2 year trial extension will provide data for longer 
term sustainability of the short cycle treatment strategy. 
Other questions remain to be answered before short 
cycle treatment can become a viable option. The trial 
was done in tightly controlled conditions with intensive 
viral load monitoring. Research is needed to understand 
whether the trial could be safely implemented in 
resource-constrained settings where routine viral 
load monitoring is unavailable or infrequent. Further 
research could also assess short cycle treatment with the 
newer long-acting drugs becoming available that have a 
higher barrier to resistance and are more tolerable, such 
as tenofovir alafenamide and dolutegravir.8
Viral suppression is the ultimate goal to improve health 
outcomes and reduce HIV transmission, thus conferring 
individual and public health beneﬁ ts.9,10 Optimum 
adherence to ART is crucial to ensure sustained virological 
suppression. Adherence to treatment of chronic illnesses 
drops oﬀ  during adolescence and unfortunately HIV 
is no exception.11 Adolescents face several barriers 
to adherence, and our experience is that no single 
intervention will be suﬃ  cient to ensure the high levels of 
adherence needed to maintain virological suppression.12 
There fore, we need several diﬀ erent approaches in our 
armamentarium to support adherence in this age group. 
We now have a promising and innovative option on the 
horizon that could be oﬀ ered to young people who face 
the prospect of taking lifelong ART.  
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